Fast inhibitory neurotransmission is mediated by synaptic GABA A and glycine receptors in the central nervous system. Gephyrin is a key anchoring protein for synaptic recruitment of both receptors. The name gephyrin is from the Greek meaning ''bridge'' and denotes its functional significance of bridging between glycine receptors and the cytoskeleton (Tyagarajan and Fritschy, 2014) . Gephyrin was first identified during purification of glycine receptors, where it co-eluted with the receptor and tubulin from rat spinal cord (Kirsch et al., 1991) . This 93 kDa protein is comprised of N-terminal gephG and C-terminal gephE domains, connected through a long unstructured linker often called the gephC domain. These domains play complex and only partially understood roles in oligomerization to concentrate receptors at synapses. In vitro, gephG assembles as a trimer and gephE assembles as a dimer, leading to the hypothesis that gephyrin forms a hexagonal lattice beneath the postsynaptic membrane to crosslink the inhibitory receptors at the postsynaptic membrane (Tyagarajan and Fritschy, 2014) . The gephC linker contains post-translational modification sites thought to regulate the formation of gephyrin clusters. Among the three domains, the gephE domain is the one that directly interacts with the inhibitory receptors. The GABA A and glycine receptors are part of the larger Cys-loop family of pentameric ligandgated ion channels. Each subunit in the pentamer shares a conserved architecture, including four transmembrane a helices (M1-M4) with a poorly conserved and often large and disordered intracellular loop between M3 and M4. It is this flexible loop that can bind to a groove in the gephE domain of gephyrin (Kim et al., 2006; Maric et al., 2011 Maric et al., , 2014 . The clearest example of this interaction is from structure-function studies of the glycine receptor b subunit with the gephE domain of gephyrin (Kim et al., 2006) .
Artemisinins are anti-malarial drugs that have been widely used for combination therapies with quinine (WHO, 2015) . Recent work suggested that gephyrin is a mammalian cellular target for artemisinins in the pancreas (Li et al., 2017) . In this study, Li et al. (2017) described that artemether turns glucagon-producing pancreas islet a cells into insulin-producing b-like cells through targeting gephyrin. They hypothesized that binding of artemether to gephyrin stabilizes the interaction between GABA A receptors and gephyrin, which somehow leads to the transdifferentiation of the a cells into the b-like cells. However, the mechanism by which this process could occur is unclear. Moreover, two recent studies have failed to reproduce the a cell to b-like cell transformation (Ackermann et al., 2018; van der Meulen et al., 2018) . While the initial finding is controversial, it led the authors of the current study to probe the interaction of artemisinins with gephyrin, which has yielded interesting results related to the interactions of inhibitory receptors at central synapses.
In this issue of Neuron, Kasaragod et al. (2019) identify the artemisinin binding site on gephyrin and provide structural and biochemical insights into the mechanism of artemisinins in gephyrinmediated inhibitory receptor clustering. After defining that the gephE domain is the target for artemisinins, they used a crystallographic approach to define atomic-scale mechanisms of the small molecules. They determined four structures of the gephE domain, two bound by the artemisinins artemether and artesunate and two bound by peptides from the intracellular loops of the GABA A a3 and glycine b receptor subunits ( Figure 1) . The structures were determined at 1.5-1.95 Å resolution, giving high confidence in the orientations and atomic interactions. Strikingly, the artemisinin binding pocket overlaps with the receptor binding pocket and shares key points of interaction, implying that these drugs may directly compete with receptor binding. The receptor-gephyrin interaction occurs in a large groove formed by gephE subdomains III and IV. Both receptor-derived peptides nestle within this hydrophobic groove. The peptides from the GABA A R a3 subunit and GlyR b subunit form key interactions with F330, I331, and R635 in gephyrin. Intriguingly, the two artemisinins are positioned to form interactions with these same residues. Kasaragod et al. (2019) took several complementary approaches to validate their crystallographic findings. First, they tested binding by isothermal titration calorimetry. Titration of peptides derived from the GABA A R a3 and GlyR b subunits with the purified gephE protein, in the presence and absence of artesunate, showed a loss in binding affinity consistent with a competitive interaction. Next, they generated mutants of residues that, from the structures, were likely to be important for the gephyrin:receptor versus gephyrin:artemisinin interactions. They measured binding affinities for artesunate and the glycine receptor peptides. While all mutants showed significantly reduced binding affinities for artesunate, F330A showed a reduction in both artesunate and peptide binding, suggesting that F330 is part of a universal binding pocket. Kasaragod et al. (2019) were interested in testing the relevance of their findings in a more physiological context. They sought to visualize the artemisinin effect on formation of gephyrin-GABA A or -glycine receptor clusters in HEK293 cells and hippocampal and spinal cord neurons. Initially, they co-expressed GFP-tagged gephyrin and the a1b glycine receptor in HEK293 cells and monitored the GFP-gephyrin self-aggregation pattern upon artemisinin treatment. With the drugs, they observed a small but statistically significant increase of large GFP-gephyrin self-aggregates in the cytosol separated from the glycine receptor, suggesting a destabilizing effect of artesunate on the gephyrinreceptor clustering in cells. They performed an analogous experiment using hippocampal and spinal cord neuronal cells and again observed drug-induced decreases in receptor-gephryin colocalization. Kasaragod et al. (2019) further explored the artemisinin effects on synaptic inhibition. They measured glycinergic currents by whole-cell patch clamp in HEK293 cells and cultured spinal cord neurons. One-hour treatment with artemisinins was sufficient to reduce glycinergic currents in the gephyrin-receptor cotransfected cells, while no change was observed using cells transfected with only the glycine receptor. Similar results were obtained from the spinal cord neurons.
This study unambiguously resolves binding of artemisinins at the same site in gephyrin thought to underlie its role in clustering inhibitory ligand-gated ion channels at synapses. The molecular details provide foundational insights for future studies probing mechanisms of receptor clustering. The actual roles of artemisinins in destabilizing synaptic signaling complexes at concentrations used to treat malaria are less clear. One challenge in studying effects of this drug class on neuronal signaling is the documented cytotoxicity in cell culture and animal studies, as well as neurotoxicity in human clinical studies (Efferth and Kaina, 2010) . Going forward, it will be exciting to visualize complexes of full receptors with gephyrin to better understand how synaptic anchoring is achieved and how small molecules may destabilize it. The center panel shows the newly defined artemisinin binding pocket in gephyrin. The side panels show the enlarged universal binding pocket with bound artemisinins and receptor peptides. Kasaragod et al. (2019) found that two artemisinins, artesunate and artemether, share a universal binding pocket with peptides from the anchoring loops of GABA A and glycine receptor subunits.
